MENU
AARD
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Aardvark Therapeutics (AARD) Ownership - Who owns Aardvark Therapeutics?

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases... Show more

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
184.17M
P/E Ratio
N/A
Total Cash
141.82M
Projected Growth
N/A
Total Debt
645K
Revenue
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
6.54
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

AARD
Capitalization
184M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
142M
Total Cash/Share
6.54
Total Debt
645K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
137M
P/B Ratio
1.34
Cash Flow
N/A
Earnings
-1.69
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
0
Current Ratio
14.04
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-40.83M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-31.22
Shares Held By Institutions
71.9M
Shares Outstanding - Current
21.7M
Total Liabilities
10.6M
Total Volume MTD
N/A
Value
1
Gain YTD
N/A
View a ticker or compare two or three
AARD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. AARD showed earnings on August 13, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details